Merck executes its own Brexit, moving all R&D operations out of UK
Less than two years after breaking ground on a ballyhooed 1 billion pound sterling ($1.31 billion) R&D center and future U.K. headquarters in London, Merck & Co. is not only…
As UK life science investments lag, ABPI spotlights country’s competitive pitfalls
One week after warning that the U.K. is undervaluing life sciences manufacturing investments, trade organization the Association of the British Pharmaceutical Industry (ABPI) has issued another call to action for…
MEI Pharma leaves biotech woes behind to rebrand as crypto company
When MEI Pharma announced it was considering its “strategic alternatives” in the wake of a failed merger last year, the options seemed pretty mundane. But, rather than winding down the…
PMV plots ovarian cancer filing after seeing midphase data
PMV Pharmaceuticals has reported a 43% response rate in a midphase ovarian cancer trial, putting the biotech on a track it believes will lead to a filing for FDA approval…
Trump admin mulls ‘severe restrictions’ on US pharmas licensing Chinese meds: NYT
The Trump administration is considering putting “severe restrictions” on the increasing flow of investigational drugs from China, according to reporting by The New York Times. A draft executive order is…
Schrödinger taps AI to speed drug discovery
Robert Abel, chief scientific officer at Schrödinger, says advanced computational tools are changing the pace and accuracy of drug discovery. In a recent episode of The Top Line podcast, Abel…
Odyssey Therapeutics heralds $213M series D to strengthen clinical portfolio
Odyssey Therapeutics’ team of seasoned drug developers is welcoming another impressive fundraising round, closing a $213 million series D after abandoning plans to go public this summer. All of Odyssey’s…
Fierce Biotech Fundraising Tracker ’25: Arthrosi adds $153M; Expedition gears up with $165M
A new year means a new Fierce Biotech Fundraising Tracker to record the significant amounts of venture capital being funneled into the industry. We’re maintaining the criteria we used for…
Fierce Biotech Layoff Tracker 2025: Ascidian Tx trims team; Ferring plots 500 layoffs
We hoped industry layoffs would relent in 2024. That’s not what happened. Overall, biopharma layoffs rose 3% last year compared to 2023, according to an analysis of yearly data. So,…